Hospital Miri 2nd Top Recruiter Globally for Respiratory Study

Standing L-R: Dr Tey Chin Wei, Dr Koh Huah Chian, Dr Andy Tang Sing Ong. Seating L-R: Salina, Dato’ Dr Fam Tem Lom, Dr Desmond Samuel(PI), Wan Ainor.

Congratulations Hospital Miri, Sarawak for being the 2nd Top Recruiter Globally for a respiratory study recently. The study team is lead by Principle Investigator, Dr. Desmond Samuel and supported by 2 of CRM’s study coordinators Ms. Salina Lisang and Wan Ainor. We hope for more great success story from the site. Thank you for making Malaysia proud!

Dr Chua Ee Yong, Sub-PI

Dr. Lee Ling Yuin, Sub-PI

 

Clinical Research Malaysia Forms Two Global Partnerships and New Foreign Investments

L-R: Dr. Akhmal Yusof (CEO of CRM), Mr. Zabidi Mahbar (Executive Director of Strategic Planning (Manufacturing), Malaysian Investment Development Authority (MIDA), YBhg Datuk Dr. Noor Hisham Abdullah (Director General of Health, Malaysia), Dr. Hytham Al-Masri (President & CEO of Hematogenix) and Dr. Yooni Kim (Executive Director, Asia Operations, Novotech)

PUTRAJAYA, 20 April 2018 – Hematogenix, a global leader in integrated laboratory services, and Novotech, Australia’s largest independent contract research organization (CRO) have both signed a Memorandum of Understanding with Clinical Research Malaysia (CRM) to establish strategic partnerships in clinical research.

The inking of this MoU with Hematogenix will have the potential to set Malaysia apart from its Asia counterparts as Hematogenix intends to invest in setting up its central laboratory services (that focuses on cancer related research and clinical trials) in this country. Hematogenix is only one of a handful of providers of such services in the USA and a leader in immune-oncology testing for drug development. The establishment of their central laboratory services will be the first of such kind in the Asia region and is anticipated to be the largest globally in due time, surpassing the one in Chicago. Through its Asia operations, Malaysia can expect to attract more global clinical trials into the country, upscale the Malaysian medical talents and bring in more investments into the nation’s economy.  Read more

New affordable hepatitis C combination treatment shows 97% cure rate

Healthcare worker examines liver of hepatitis C patient in Thailand

Results support a public health approach to hepatitis C

An affordable hepatitis C combination treatment including the new drug candidate ravidasvir has been shown to be safe and effective, with extremely high cure rates for patients, including hard-to-treat cases, according to interim results from the Phase II/III STORM-C-1 trial presented by the non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) at the International Liver Conference in Paris.

[Bahasa Malaysia] [Español] [Français] [Mandarin Chinese] [Português] [Tamil]

Read more

Sultan of Johor Announces Tunku Laksamana Johor Cancer Centre

JOHOR BAHRU, Malaysia, April 2, 2018 /PRNewswire/ — His Majesty Sultan Ibrahim Ibni Almarhum Sultan Iskandar, the Sultan of Johor, announced yesterday the establishment of a regional centre for cancer treatment, research and education, led by Singapore-headquartered Asian American Medical Group (“AAMG”).

The Tunku Laksamana Johor Cancer Centre (“TLJCC”) is  slated for an end-2020 opening in Iskandar Puteri. Its first phase will offer:

i.          Diagnostics and imaging: PET/CT, CT/MRI with liquid biopsy;
ii.         Personalised oncology using gene profiling and targeted chemo/immunotherapy; and
iii.        Radiation therapy: IMRT, SBRT and VMAT. Read more

Malaysia to generate healthcare revenue RM2.8b by 2020

KUALA LUMPUR: Malaysia has been recognised as the Health & Medical Tourism: Destination of the Year for three consecutive years from 2015 to 2017 by the International Medical Travel Journal (IMTJ).

The National Tarnsformation Programme (NTP) 2017 Annual Report also noted that the country was eyeing to generate hospital revenue of RM2.8 billion by 2020, with target markets in Indonesia, Myanmar, China and Vietnam. Read more

Malaysian medical physicist wins Marie Curie award

Breast cancer researcher Prof Dr Ng Kwan Hoong from Universiti Malaya’s Medicine Faculty received the award for his efforts in improving early detection by using artificial intelligence in computer-aided diagnosis. — Picture by Rudyanto Wijaya/shutterstock.com

KUALA LUMPUR, March 19 — A breast cancer researcher has become the first Malaysian to win the Marie-Sklodowska Curie Award.

The Star reported that Prof Dr Ng Kwan Hoong from Universiti Malaya’s Medicine Faculty received the award for his efforts in improving early detection by using artificial intelligence in computer-aided diagnosis. Read more

Researchers from University of Malaya aimed to develop a lateral flow-RPA technique to diagnose knowlesi malaria efficiently and rapidly

Researchers from University of Malaya, Malaysia, aimed to develop a lateral flow-RPA technique to diagnose knowlesi malaria efficiently and rapidly. Read more

Big pharma against CL move but WHO agrees

Right to get treatment: It was reported last year that there were 400,000 Hepatitis C sufferers in Malaysia, with only a fraction who could afford the RM300,000 cost. — AFP

KUALA LUMPUR: Malaysia’s bold move to impose compulsory licence (CL) on the drug sofosbuvir has been heavily criticised by big pharmaceutical companies, but has the support of the World Health Organisation (WHO).

WHO advocates universal health coverage and that means access to life-saving treatment, said its head of mission and representative to Malaysia, Brunei and Singapore Dr Lo Ying-Ru. Read more

Hope for Hepatitis C patients

KUALA LUMPUR: Two months after Malaysia received world recognition for taking steps to provide affordable medicine for Hepatitis C sufferers, it is learnt that 18 state hospitals are ready to roll out the treatment, with up to 400,000 patients likely to benefit.

This access to the affordable medicine comes after the Government issued a compulsory licence (CL) to import or produce the generic versions of sofosbuvir one of the drug combinations used for Hepatitis C treatment.

The combination of sofosbuvir and daclatasvir is now available in all government state hospitals. Read more

Naluri Hidup closes $258k seed round from BioMark, 500 Startups

Malaysia-based digital health startup Naluri Hidup has raised approximately RM1 million ($258,570) in seed financing from Singapore-based healthcare analytics firm BioMark and Silicon Valley’s 500 Startups through its Southeast Asia-focussed fund, 500 Durians.

Investment proceeds from this round, including seed capital from its founders, will finance the development of the Naluri digital platform, as well as commercial and clinical trials with Naluri’s industry partners. The company works with insurers, employers and hospitals to offer a health psychology based preventive health program for at-risk policyholders and employees, and a rehabilitative program for chronic illness patients. Read more